Insense
Stage
Other Investors | AliveAbout Insense
Insense Ltd has developed and patented a technology platform centred on the feature of in-situ wound oxygenation. Its first products, Oxyzyme and Iodozyme, target chronic wounds and will be launched into the professional healthcare market.
Loading...
Loading...
Insense Patents
Insense has filed 9 patents.
The 3 most popular patent topics include:
- amino acids
- autosomal recessive disorders
- job scheduling
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/16/2014 | 4/25/2017 | Sensors, Integrated circuits, Microtechnology, Semiconductor device fabrication, Nanotechnology | Grant |
Application Date | 6/16/2014 |
|---|---|
Grant Date | 4/25/2017 |
Title | |
Related Topics | Sensors, Integrated circuits, Microtechnology, Semiconductor device fabrication, Nanotechnology |
Status | Grant |
Latest Insense News
Apr 10, 2023
April 10, 2023 Insense Health Tech Company, which implemented the “inEpilepsy” application that warns patients and their relatives visually and audibly up to 180 seconds before the epileptic seizure occurs, and IKAR Holding, which was founded in London in 2019 and invests in small and medium-sized companies operating in different sectors, including technology. announced that they were opening up to the global by establishing a partnership. Developed by Insense Health Tech Company and having “Seizure Detection and Tracking Software”, inEpilepsy is the first epilepsy application in the world. The application also helps epilepsy patients overcome seizures that negatively affect their comfort of life, with the least risk. With the inEpilepsy application, the data is instantly shared with the patients’ own doctors with the expert opinion and expert follow-up feature, if desired. In this way, doctors have the opportunity to get to know their patients more closely, as they have more information about the process. At the same time, the application also makes a reminder by recording the time of use and doses of the drugs. In this way, epilepsy patients can continue their treatment without interruption. It is aimed to reach 1 million epilepsy patients by 2023. Saying that as IKAR Holdings, they are excited to partner with Insense Health Tech Company to bring this innovative technology to epilepsy patients around the world, IKAR Holding Chairman of the Board Mario Diel said, “This partnership will help improve the quality of life of epilepsy patients and provide them with the best possible care. will be,” he said. Yasin Sönmez, CEO of Insense Health Tech Company, who stated that as a company, they are dedicated to providing the best possible care to epilepsy patients, said, “We are confident that this partnership will help make a difference in the lives of people affected by epilepsy.” Ulaş Kayacan, Founding Partner of Insense Health Tech Company, said that their goal is to reach 1 million epilepsy patients in 2023. According to the statement of the parties, the cooperation was realized on the basis of a valuation of 30 million euros. The said investment will be used to enable the application to reach epilepsy patients in different parts of the world.
Insense Frequently Asked Questions (FAQ)
What is Insense's latest funding round?
Insense's latest funding round is Other Investors.
Who are the investors of Insense?
Investors of Insense include Unilever Ventures.
Who are Insense's competitors?
Competitors of Insense include Relievant Medsystems, AlterG, SetPoint Medical, ALung Technologies, Promedtek and 7 more.
Loading...
Compare Insense to Competitors
SetPoint Medical develops implantable bioelectronic therapies to treat chronic inflammatory diseases.. It aims to treat patients with chronic autoimmune diseases and provides a treatment alternative for rheumatoid arthritis, inflammatory bowel disease, and other chronic autoimmune conditions. It was formerly known as Innovative Metabolics. The company was founded in 2007 and is based in Valencia, California.
Portaero, in stealth mode, is a medical devices firm, developing a device for the treatment of COPD (Chronic obstructive pulmonary disease).
NeuroTrax is a company focused on brain health, operating in the healthcare and technology sectors. The company offers a computerized testing solution, BrainCare, which provides objective tests across various cognitive areas, graphical reports of patient progress, and evidence-based recommendations for brain training to promote wellness. The primary customers of NeuroTrax are clinicians, patients and their families, and researchers in the healthcare industry. It was founded in 2000 and is based in Newark, New Jersey.
2nd place finisher at the 2009 BYU Business Plan Competition. KT Tape brings kinesiology therapeutic tape directly to the consumers. The tape has the same elasticity as skin and relieves pain by lifting skin off of the injured location to increase circulation. KT Tape already has an exclusive endorsement from Kerri Walsh -- U.S. Olympic volleyball player who wore the tape at the Beijing Olympics
Stealth mode medical device company developing devices for drug delivery. Monterey Devices submitted a patent on device for buffering anesthetics.
Trigemina is focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products. Trigemina's lead product candidate, TI-001, is a patented new application of oxytocin. TI-001 has shown promising results for use as a safe and effective therapy for all forms of chronic and subacute head pain.
Loading...